Clinical trial
High Dose Trial in COPD
NCT00128440 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00128440 |
|---|---|
| Title | High Dose Trial in COPD |
| Official title | A Randomized, Multiple-dose, Double-Blind, Crossover Study to Compare the Efficacy and Safety of 200 μg and 400 μg of BEA 2180 BR to Tiotropium 5 μg and Placebo When Each is Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD) |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Drug |
| Interventions | BEA 2180 BR, tiotropium |
| Enrollment | 78 |
| Start date | Aug 1, 2005 |
| Primary completion | Sep 1, 2006 |
| First posted | Aug 10, 2005 |
| Last update posted | Oct 29, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: